| scholarly article | Q13442814 |
| P2093 | author name string | Maria R Baer | |
| Zhe-Sheng Chen | |||
| Suresh V Ambudkar | |||
| Mehmet Burcu | |||
| Suneet Shukla | |||
| Karthika Natarajan | |||
| Jasjeet Bhullar | |||
| P2860 | cites work | The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells | Q24302137 |
| The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG | Q24311816 | ||
| The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs | Q24336934 | ||
| The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias | Q24339375 | ||
| PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers | Q24603099 | ||
| Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1 | Q24655144 | ||
| Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation | Q28297726 | ||
| Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling | Q28572558 | ||
| Targeting multidrug resistance in cancer | Q29616803 | ||
| Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. | Q30444746 | ||
| miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts | Q30496174 | ||
| Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia | Q30497200 | ||
| Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells | Q32016277 | ||
| Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers | Q73563720 | ||
| Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2 | Q80777899 | ||
| Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism | Q83016190 | ||
| ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia | Q83895091 | ||
| Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump | Q33204719 | ||
| The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype | Q33243645 | ||
| Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib | Q33566582 | ||
| Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes | Q33597393 | ||
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ | Q34118184 | ||
| P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 | Q34124919 | ||
| VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein | Q34304819 | ||
| Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 | Q34360283 | ||
| MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. | Q34412520 | ||
| Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1 | Q35007411 | ||
| Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein | Q35076190 | ||
| Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia | Q35125923 | ||
| The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2 | Q36933169 | ||
| Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. | Q37188016 | ||
| Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells | Q37414714 | ||
| The proto-oncogene Pim-1 is a target of miR-33a | Q39509450 | ||
| MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma | Q39521098 | ||
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation | Q39747662 | ||
| Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters | Q39854362 | ||
| Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment | Q39874804 | ||
| Constitutively activated FLT3 phosphorylates BAD partially through pim-1. | Q40251345 | ||
| The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. | Q40254927 | ||
| Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia | Q40442997 | ||
| Cyclosporin A is a broad-spectrum multidrug resistance modulator | Q40443016 | ||
| Gefitinib reverses breast cancer resistance protein-mediated drug resistance | Q40515752 | ||
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro | Q40571040 | ||
| Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line | Q40907899 | ||
| Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. | Q40968389 | ||
| Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression | Q42163903 | ||
| Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. | Q42678165 | ||
| Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells | Q42827076 | ||
| Discovery of imidazo[1,2-b]pyridazine derivatives as IKKβ inhibitors. Part 1: Hit-to-lead study and structure–activity relationship | Q42950439 | ||
| P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor | Q42952483 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| Flow cytometric analysis of breast cancer resistance protein expression and function. | Q44063189 | ||
| Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | Q44083625 | ||
| Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources | Q44578925 | ||
| P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate | Q44729076 | ||
| Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Q44769964 | ||
| Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors | Q44841683 | ||
| The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors | Q45072250 | ||
| Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias | Q45178457 | ||
| The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 | ||
| Interleukin-5 regulates genes involved in B-cell terminal maturation. | Q53606509 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 514-524 | |
| P577 | publication date | 2012-12-19 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms | |
| P478 | volume | 85 |
| Q36962615 | A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function |
| Q39049159 | ABCG2/BCRP: Specific and Nonspecific Modulators. |
| Q48228703 | Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. |
| Q87993866 | Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions |
| Q38715353 | Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. |
| Q90613746 | Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism |
| Q99233801 | Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications |
| Q37218015 | Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1 |
| Q89737199 | MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs |
| Q38836775 | Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors |
| Q92876672 | Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor |
| Q48301559 | Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. |
| Q38209606 | PIM kinases: an overview in tumors and recent advances in pancreatic cancer |
| Q37233255 | PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value |
| Q40066265 | PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia |
| Q38960311 | Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. |
| Q35005230 | Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma |
| Q28273475 | Pim-1 kinase as cancer drug target: An update |
| Q42380771 | Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia |
| Q90348212 | SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines |
| Q92663055 | Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs |
| Q28255361 | Targeting Pim kinases for cancer treatment: opportunities and challenges |
| Q26799499 | Targeting the Pim kinases in multiple myeloma |
| Q38710502 | Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo |
| Q92442405 | The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs |
| Q57283047 | The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines |
| Q91525301 | The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| Q47821418 | Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. |
Search more.